Key result
Malignant intracardiac masses carry poor survival, with all patients dying within ~31 months.
Why the study?
Intracardiac masses are rare and pose significant diagnostic and therapeutic challenges, with limited effective treatments especially for malignant tumors.
Case Report (n=5)
No
Malignant primary cardiac tumors carry an extremely poor prognosis despite aggressive multimodal therapy, underscoring the critical need for early diagnosis and complete surgical resection.
Answers are grounded in this paper and cite their sources.
Malignant intracardiac masses carry dismal prognosis despite multimodal care; this Level 5 series leaves open optimal strategies for early detection and resection.
Intracardiac mass is a rare condition that poses significant diagnostic and therapeutic challenges. Regardless of the pathological diagnosis, these cases are often difficult to manage, as patients typically present with urgent clinical symptoms at their initial visit. Most symptoms result from blood flow disturbances caused by a large intracardiac tumor. Furthermore, patients face a high risk of thromboembolism. Herein, we present five cases of intracardiac masses, including three malignant tumors, encountered over approximately two years. Each case had a different pathological diagnosis: angiosarcoma (n = 2), undifferentiated pleomorphic sarcoma (n = 1), benign myxoma (n = 1), and a simple ball thrombus (n = 1). Early and accurate diagnosis and treatment, ideally complete surgical resection, is the primary approach to managing intracardiac mass. However, extensive tumor resection can be difficult to achieve while preserving adequate cardiac function, especially in advanced-stage cases. In our series, surgical resection was not indicated for two patients (one with a ball thrombus and the other with angiosarcoma) due to impaired consciousness from multiple cerebral thromboembolism or advanced-stage sarcoma. The remaining three patients, diagnosed with myxoma, angiosarcoma, and undifferentiated pleomorphic sarcoma, underwent tumor excision. However, in the two malignant cases, early recurrence occurred, and postoperative management proved to be extremely challenging. The three patients with primary cardiac sarcoma received radiation therapy combined with chemotherapy or multiple chemotherapy regimens as either primary or secondary treatment. Of the two patients diagnosed with angiosarcoma, one died two months after admission without undergoing surgery, while the other died 11 months following tumor resection, highlighting the limited effectiveness of available treatments. The remaining patient, diagnosed with undifferentiated pleomorphic sarcoma, also received combination therapy with radiation and chemotherapy. In this case, the primary in the left atrium and a solitary metastasis to the left adrenal gland were relatively controlled with proton beam therapy. In cases of intracardiac mass, early diagnosis and prompt surgical excision are crucial. If the tumor is malignant, combined treatment with radiation and chemotherapy should be promptly considered as a second-line approach based on the tumor's characteristics and the extent of surgical resection. However, there are currently no curative treatments for either malignant or benign primary cardiac tumors other than complete tumor excision. Therefore, early-stage diagnosis is directly linked to improved prognosis.
No takes yet. Share an insight, caveat, or question.
Shinji Akishima (2025) conducted a case report in Intracardiac mass (n=5). Surgical resection and multimodal therapy was evaluated on Survival. Among five patients with intracardiac masses, the four with malignant or inoperable lesions died within 31 months, while the single patient with a benign myxoma survived beyond 5 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: